Table 1 Input parameters for cost-effectiveness analysis

Clinical event probabilities (monthly)

Progression disease

abiraterone group

0.0047

0.00423–00517

beta

[27]

enzalutamide group

0.0024

0.00216-.00264

beta

Death in progression state

abiraterone group

0.0019

0.00171-.00209

beta

[27]

enzalutamide group

0.0021

0.00189-.0023

beta

Death in progression free survival state

abiraterone group

0.009

0.0081-.0099

beta

[27]

enzalutamide group

0.008

0.0072-.0088

beta

AE^*in abiraterone group (monthly)

Anemia

0.007

0.006-.008

beta

[28]

Backpain

0.033

0.028-.038

beta

[28]

Bone pain

0.084

0.071-.097

beta

[29]

Diarrhea

0.018

0.015-.021

beta

[28]

Fatigue

0.05

0.043-.058

beta

[28]

Neutropenia

0.003

0.0026-.0035

beta

[28]

Vomiting

0.022

0.019-.025

beta

[28]

AE in enzalutamide group (monthly)

Anemia

0.005

0.004-.006

beta

[30, 31]

Backpain

0.084

0.071-.097

beta

[30, 31]

Arthralgia

0.017

0.014-.02

beta

[30, 31]

Diarrhea

0.013

0.011-.015

beta

[30, 31]

Fatigue

0.033

0.028-.038

beta

[30, 31]

vomiting

0.02

0.017-.023

beta

[30, 31]

Utility

Progression-free

0.61

0.55-.68

beta

[32]

progression

0.31

0.28-.35

beta

[32]

Disutility anemia

0.11

0.099-.12

beta

[32]

Disutility backpain

0.06

0.054-.066

beta

[32]

Disutility bone pain

0.06

0.054-.066

beta

[32]

Disutility diarrhoea

0.2

0.18-.22

beta

[32]

Disutility fatigue

0.47

0.42-.52

beta

[32]

Disutility neutropenia

0.1

0.09-.12

beta

[32]

Disutility arthralgia

0.041

0.035-.047

beta

[33]

Disutility vomiting

0.09

0.07-.104

beta

[33]

Cost ($)

enzalutamide

24$

19.2–28.8

gamma

https://irc.fda.gov.ir/nfi

abiraterone

13$

10.4–15.6

gamma

https://irc.fda.gov.ir/nfi

Laboratory tests

319$

255–386

gamma

https://treatment.tums.ac.ir

Imaging

213$

170–255

gamma

https://treatment.tums.ac.ir

Bone protecting agent

3,400$

2,720-4,080

gamma

https://treatment.tums.ac.ir

Radiopharmaceutical

6,853$

5,482-8,223

gamma

https://treatment.tums.ac.ir

Hospitalization

1,763$

1,410-2,115

gamma

https://treatment.tums.ac.ir

Chemotherapy

10,287 $

8,229 − 12,324

gamma

https://treatment.tums.ac.ir

Anemia

166$

141–191

gamma

https://treatment.tums.ac.ir

Backpain

84$

71–95

gamma

https://treatment.tums.ac.ir

Bone pain

95$

81–109

gamma

https://treatment.tums.ac.ir

Diarrhea

52$

44–60

gamma

https://treatment.tums.ac.ir

Fatigue

131$

111–151

gamma

https://treatment.tums.ac.ir

Neutropenia

154$

131–177

gamma

https://treatment.tums.ac.ir

Vomiting

85$

72–98

gamma

https://treatment.tums.ac.ir

Direct non-medical cost

enzalutamide group

1,549 $

1,239-1,858

gamma

Interview

abiraterone group

2,132 $

1,705-2,558

gamma

Indirect cost

enzalutamide group

5,179 $

4,143-6,214

gamma

Interview

abiraterone group

6,906 $

5,524-8,287

gamma